Oramed Pharmaceuticals (ORMP)

Executive Summary

Oramed Pharmaceuticals is a clinical-stage biotech company pioneering an oral delivery platform for drugs traditionally administered via injection. Its lead candidate, ORMD-0801, is an oral insulin formulation targeting type 2 diabetes, which is currently in a Phase 3 trial (NCT06731075) that began recruiting in December 2025. The company has also explored ORMD-0801 in non-alcoholic steatohepatitis (NASH) with completed Phase 2 studies. Oramed's proprietary technology has the potential to transform diabetes management by offering a needle-free alternative, addressing a large and growing market. Despite past setbacks, including a terminated Phase 3 trial in 2023, the ongoing Phase 3 study represents a critical milestone with the potential to validate the platform's efficacy and safety. Oramed's near-term outlook hinges on successful execution of its Phase 3 program and strategic partnerships. The company may provide interim data updates or enrollment completion milestones in the coming quarters. Additionally, licensing deals for its oral delivery platform with other peptide therapeutics remain a possibility, which could unlock significant value. However, the stock remains speculative given the historical challenges in developing oral insulin. Key upcoming catalysts include Phase 3 interim data, potential FDA interactions, and partnership announcements, which could drive significant stock movement.

Upcoming Catalysts (preview)

• H2 2026Phase 3 Interim Data for ORMD-0801 in Type 2 Diabetes50% success
• 2026Partnership or Licensing Deal for Oral Delivery Platform40% success
• 2026FDA Meeting or Regulatory Update on Phase 3 Program70% success